Company intelligence / Profile preview

Right Brain Bio

Westchester County, New York, United Statesrightbrainbio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Right Brain Bio has developed RB-190, a repurposed form of metyrosine, based on the discovery that excess intracellular dopamine causes neurodegeneration in Parkinson’s disease. Preclinical studies in nine models have shown reversal of pathology. The FDA has reviewed the data and confirmed readiness for an IND submission for a Phase 2 trial.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

PRO-190

1 more asset in the full pipeline.

Request access →

Partnerships

Suven Pharmaceuticals (manufacturing partner for RB-190)

Beyond the preview

Go deeper on Right Brain Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Right Brain Bio.

Explore the full profile